Biotie Therapies - Major shareholder announcements

Biotie Therapies Oyj :Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

BIOTIE THERAPIES CORP.             STOCK EXCHANGE RELEASE       December
14, 2015 at 3.00 p.m.

Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act

Biotie Therapies Corp. (Nasdaq Helsinki BTH1V; NASDAQ: BITI) ("Biotie" or the
"Company") has on December 12, 2015 received a notification in accordance with
Chapter 9, Section 5 of the Finnish Securities Markets Act from Vivo Capital
VIII, LLC on behalf of itself and Vivo Capital Fund VIII, L.P. as a result of
the implementation of changes to the transparency directive in the Finnish
Securities Market Act.

According to the notification, the total number of Biotie shares owned directly
or through financial instruments by Vivo Capital VIII, LLC and its funds was
13.76 per cent of Biotie's total number of shares and voting rights on 26
November 2015. Biotie's registered total number of shares and voting rights
amounting to 1,086,940,271 has been used in the calculation of percentages for
the announcement.

Total positions of Vivo Capital VIII, LLC and its funds subject to the
notification:

+-----------------------+----------------+---------------------+---------------+
|                       |% of shares and |% of shares and      |Total of both  |
|                       |voting rights   |voting rights through|in % (A + B)   |
|                       |(total of A)    |financial instruments|               |
|                       |                |(total of B)         |               |
+-----------------------+----------------+---------------------+---------------+
|Resulting situation on |8.98            |4.78                 |13.76          |
|the date on which      |                |                     |               |
|threshold was crossed  |                |                     |               |
|or reached             |                |                     |               |
+-----------------------+----------------+---------------------+---------------+
|Position of previous   |9.95            |N/A                  |N/A            |
|notification (if       |                |                     |               |
|applicable)            |                |                     |               |
+-----------------------+----------------+---------------------+---------------+

Notified details of the resulting situation on the date on which the threshold
was crossed or reached:

A: Shares and voting rights

+----------------------+----------------------------+--------------------------+
|Class/type of shares  |Number of shares and voting |% of shares and voting    |
|ISIN code (if         |rights                      |rights                    |
|possible)             +---------+------------------+---------+----------------+
|                      |Direct   |Indirect          |Direct   |Indirect        |
|                      |(SMA 9:5)|(SMA 9:6 and 9:7) |(SMA 9:5)|(SMA 9:6 and    |
|                      |         |                  |         |9:7)            |
+----------------------+---------+------------------+---------+----------------+
|Shares                |-        |51,944,445        |-        |4.78            |
|(FI0009011571)        |         |                  |         |                |
+----------------------+---------+------------------+---------+----------------+
|Shares                |-        |45,674,320        |-        |4.20            |
|(FI0009011571)        |         |                  |         |                |
|represented by        |         |                  |         |                |
|570,929 ADSs          |         |                  |         |                |
+----------------------+---------+------------------+---------+----------------+
|                      |         |                  |         |                |
+----------------------+---------+------------------+---------+----------------+
|SUBTOTAL A            |97,618,765                  |8.98                      |
+----------------------+----------------------------+--------------------------+

For further information on the ADSs representing the Company's shares, the
notification refers to the stock exchange release issued by the Company on June
11, 2015.

B: Financial instruments according to SMA 9:6a

+-----------------+------------+------------+------------+------------+--------+
|Type of financial|Expiration  |Exercise/   |Physical or |Number of   |% of    |
|instrument       |date        |Conversion  |cash        |shares and  |shares  |
|                 |            |period      |settlement  |voting      |and     |
|                 |            |            |            |rights      |voting  |
|                 |            |            |            |            |rights  |
+-----------------+------------+------------+------------+------------+--------+
|Warrants         |Nov 1, 2020 |Nov 1, 2015 |Physical    |51,944,445  |4.78    |
|entitling to     |            |- Nov       |settlement  |            |        |
|shares (new or   |            |1, 2020     |            |            |        |
|treasury shares) |            |            |            |            |        |
|(FI0009011571)   |            |            |            |            |        |
+-----------------+------------+------------+------------+------------+--------+
|                 |            |            |            |            |        |
+-----------------+------------+------------+------------+------------+--------+
                                            |SUBTOTAL B  |51,944,445  |4.78    |
                                            +------------+------------+--------+

For further information on the warrants, the notification refers to the stock
exchange release issued by the Company on April 23, 2015.

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity:

+--------------------+-------------------+-----------------------+-------------+
|Name                |% of shares and    |% of shares and voting |Total of both|
|                    |voting rights      |rights through         |             |
|                    |                   |financial instruments  |             |
+--------------------+-------------------+-----------------------+-------------+
|Vivo Capital VIII,  |0                  |0                      |0            |
|LLC                 |                   |                       |             |
+--------------------+-------------------+-----------------------+-------------+
|Vivo Capital Fund   |7.89               |4.20                   |12.09        |
|VIII, L.P.          |                   |                       |             |
+--------------------+-------------------+-----------------------+-------------+
|Vivo Capital Surplus|1.09               |0.58                   |1.67         |
|Fund VIII, L.P.     |                   |                       |             |
+--------------------+-------------------+-----------------------+-------------+

According to the notification, Vivo Capital VIII, LLC is the general partner of
(i) Vivo Capital Fund VIII, L.P. and (ii) Vivo Capital Surplus Fund VIII, L.P.
Further according to the notification, neither Vivo Capital VIII, LLC nor any
other entity under its control, other than (i) Vivo Capital Fund VIII, L.P. and
(ii) Vivo Capital Surplus Fund VIII, L.P., holds any shares or financial
instruments in the Company.



In Turku, December 14, 2015

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Investor Relations Manager, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:

NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com






[HUG#1973294]